Today’s standard of care for advanced PCa includes gonadotropin-releasing hormone agonists (leuprolide), second-generation nonsteroidal AR antagonists (apalutamide, enzalutamide and darolutamide) and the androgen biosynthesis inhibitor abiraterone [11]. The gene discussed is AR; the disease is posterior cortical atrophy.